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Abstract 
Tapasin and TAPBPR are known to perform peptide editing on major histocompatibility 
complex class I (MHC I) molecules, however, the precise molecular mechanism(s) involved 
in this process remain largely enigmatic. Here, using immunopeptidomics in combination 
with novel cell-based assays that assess TAPBPR-mediate peptide exchange, we reveal a 
critical role for the K22-D35 loop of TAPBPR in mediating peptide exchange on MHC I. We 
identify a specific leucine within this loop that enables TAPBPR to facilitate peptide 
dissociation from MHC I. Moreover, we delineate the molecular features of the MHC I F 
pocket required for TAPBPR to promote peptide dissociation in a loop-dependent manner.  
These data reveal that chaperone-mediated peptide editing of MHC I can occur by different 
mechanisms dependent on the C-terminal residue that the MHC I accommodates in its F 
pocket and provide novel insights that may inform the therapeutic potential of TAPBPR 
manipulation to increase tumour immunogenicity.    
 
Keywords: antigen processing and presentation, human leukocyte antigen (HLA), 
TAPBPR/TAPBPL 
 
Impact Statement  
Immunopeptidomics in combination with novel cell-based assays that assess peptide 
exchange reveal a critical role for the K22-D35 loop of TAPBPR in mediating peptide 
dissociation and peptide selection on MHC I. 
 
  
Introduction 
Major histocompatibility complex class I (MHC I) molecules play a critical role in 
immmunosurveillance, particularly in the context of viral infections and cancer, by presenting 
antigenic peptides to CD8+ T cells. Prior to their cell surface export, MHC I molecules 
undergo peptide editing, a process that involves the exchange of low-affinity peptides for 
those of higher affinity. In addition to ensuring that only stable peptide:MHC I complexes are 
released to the plasma membrane, peptide editing ultimately controls the peptide repertoire 
that is displayed for immune detection. For over two decades, tapasin was the only known 
peptide editor for MHC I, facilitating peptide selection within the confines of the peptide 
loading complex (PLC)[1-4]. However, it is now well-recognised that the tapasin-related 
protein TAPBPR is a second independent peptide editor that performs peptide exchange 
outside the PLC [5-8]. Furthermore, TAPBPR can work in cooperation with UDP-
glucose:glycoprotein glucosyltransferase 1 to reglucosylate MHC I, causing recycling of 
MHC molecules to the PLC [9].  
 
Although TAPBPR usually functions as an intracellular peptide editor, we have recently 
made the fascinating discovery that when given access to surface expressed MHC I 
molecules, TAPBPR retains its function as a peptide exchange catalyst, and can be utilised to 
display immunogenic peptides of choice directly onto the surface of cells [10]. We have 
therefore identified that manipulation of TAPBPR function may be utilised as a potential 
immunotherapeutic that facilitates the presentation of both neoantigens and viral-derived 
peptides, thereby overriding the endogenous cellular antigen processing pathway. Moreover, 
we have also developed two novel functional assays that enable detailed interrogation of 
TAPBPR-mediated peptide exchange on MHC class I [10]. 
 Precisely how tapasin and TAPBPR function at the molecular level remains largely 
enigmatic.  The recently reported crystal structures of human TAPBPR in complex with 
mouse MHC I captured the endpoint of peptide editing, thereby suggesting that TAPBPR 
facilitates peptide exchange by widening the peptide-binding groove of MHC I at the α2-1 
region [11,12]. However, there remains an incomplete understanding of the step-by-step 
processes by which the two peptide editors, TAPBPR and tapasin, recognise peptide-loaded 
MHC I molecules and actively facilitate peptide dissociation to result in the conformations 
observed in the crystal structures. Indeed McShan et al., have recently used NMR in an 
attempt to further delineate the dynamic process of peptide exchange on MHC I by TAPBPR 
[13].  
 
Intriguingly, the structure reported by Thomas & Tampe identified a loop of TAPBPR that 
was proposed to interact with the peptide-binding groove of MHC I, where the C-terminus of 
bound peptide usually resides [12]. While this study demonstrated the localisation of the 
loop, to date, there is no experimental evidence to support the notion that this loop mediates 
peptide exchange on MHC I. In contrast, Jiang et al. failed to capture the loop in  proximity 
to the peptide-binding groove [11], further questioning the relevance and importance of this 
loop in TAPBPR-mediated peptide exchange. Given the discordance between the data 
reported for the captured structures and the lack of functional evidence to support any role for 
this loop, it is vital to reconcile these discrepancies to understand whether the TAPBPR loop 
is involved in peptide exchange.  
Here, we investigate the functional importance of the K22-D35 loop using two newly 
developed assays in combination with immunopeptidomic analysis. Our data demonstrates 
that this loop is critical for peptide dissociation from MHC I. Furthermore, we highlight key 
molecular features governing TAPBPR:MHC I interaction and provide insight into the 
mechanism(s) of peptide selection on MHC I molecules.   
  
Results 
The TAPBPR K22-D35 loop lies at the interface with the MHC I peptide binding groove  
Prior to the recent determination of the TAPBPR-MHC I crystal structures [11,12], we 
docked our model of TAPBPR onto a previously determined structure of HLA-A2, using our 
mutagenesis data that identified critical regions in the TAPBPR-MHC I interface [6]. Our 
docking identified a region of TAPBPR that lies close to the peptide-binding groove of MHC 
I, in the proximity of the F pocket (Fig. 1a, dotted circle). This region contained a loop that 
differs between tapasin and TAPBPR. In tapasin, this loop appears to be rather short and is 
not sufficiently well ordered in the crystal structure to be visible [14], while in TAPBPR this 
loop is significantly longer (Fig. 1b). The two crystal structures of the TAPBPR-MHC I 
complex support our prediction regarding the arrangement of TAPBPR relative to MHC I, 
including this loop region being very near the F pocket (Fig. 1c). However, the position and 
orientation of the loop in the structures is poorly defined. In the structure from Jiang et al 
[11], this loop is not sufficiently well ordered to be modelled. In the structure from Thomas & 
Tampe [12], the loop has been modelled, however the electron density into which it was built 
is not well defined: several side chains and even several of the backbone atoms do not fit the 
electron density well (Fig. 1d). It is likely that alternative orientations of the loop would also 
satisfy the crystallographic data presented. Therefore, it is critically important to verify 
whether there is any functional role of this loop in peptide editing.  
 
TAPBPR loop mutants are stably expressed and bind MHC I and UGT1 
To test whether the K22-D35 loop of TAPBPR was a functionally important region for 
mediating peptide selection, we first replaced all the residues in the loop with either glycine, 
alanine or serine, to produce a TAPBPR variant with a potentially functionless loop 
(TAPBPRØloop)(Table 1). More subtle mutations of this loop were designed based on the 
work by Springer and colleagues, who demonstrated that dipeptides carrying long 
hydrophobic residues are able to bind to the peptide-binding groove of recombinant MHC I 
and enhance peptide dissociation [15]. Thus, we explored whether a leucine residue at 
position 30 of the mature TAPBPR protein, the only long hydrophobic residue within the 
entire loop, was involved in peptide exchange on MHC I.  We created two TAPBPR variants 
in order to test this. First, we replaced the leucine with glycine in the TAPBPRWT molecule 
(TAPBPRL30G).  Second, we reintroduced leucine 30 into TAPBPR with the dysfunctional 
loop (TAPBPRØG30L) (Table 1). Upon transduction into TAPBPR-deficient HeLaM cells 
(HeLaM-TAPBPRKO), steady state expression of all the TAPBPR loop mutants was similar 
to TAPBPRWT and all variants interacted equally well with both MHC I and UGT1 (Fig.  
1e), suggesting the overall protein stability and structure of TAPBPR was not significantly 
affected by the changes to the loop.  
 
The K22-D35 loop is essential for mediating peptide exchange on HLA-A*68:02 
Recently, we have developed two novel assays which can be used to measure TAPBPR-
mediated peptide exchange on MHC I molecules. The first assay established takes advantage 
of the small proportion of TAPBPR that escapes to the cell surface upon its over-expression 
in cell lines [10]. We have demonstrated that plasma membrane expressed wild-type 
TAPBPR efficiently mediates peptide exchange on cell surface HLA-A*68:02 molecules 
found on HeLaM cells [10]. We have previously demonstrated that TAPBPR-mediated 
peptide exchange in this assay occurs directly on the cell surface, given that it works on cells 
incubated at 4oC, which inhibits membrane trafficking [10]. To initially explore the 
functional importance of the K22-D35 loop, we tested whether plasma membrane expressed 
TAPBPRØloop was capable of mediating peptide exchange on HLA-A*68:02 to a similar 
extent as TAPBPRWT. When exploring the ability of TAPBPR to promote peptide 
association, we found plasma membrane expressed TAPBPRØloop enhanced the binding of 
an exogenous fluorescent peptide specific for HLA-A*68:02 (YVVPFVAK*V) onto cells to 
a similar extent as TAPBPRWT (Fig. 2a). This may be due, in part, to TAPBPR enhancing 
the trafficking of associated, peptide-receptive MHC I with it through the secretory pathway. 
However, when we tested the ability of TAPBPR to mediate peptide dissociation (i.e. 
removal of the bound fluorescent peptide in the presence of an unlabelled competitor peptide) 
(Fig. 2b), in contrast to the efficient exchange observed with TAPBPRWT, very little, if any, 
dissociation of fluorescent peptide was observed with TAPBPRØloop (Fig. 2c-2e). This 
suggests that the K22-D35 loop of TAPBPR is essential for mediating efficient peptide 
dissociation from HLA-A*68:02.   
 
L30 is a critical residue of TAPBPR for peptide exchange on HLA-A*68:02 
Next, we tested the ability of both plasma membrane bound TAPBPRL30G and 
TAPBPRØG30L to promote peptide exchange in our assay. As observed above with 
TAPBPRØloop, plasma membrane expressed TAPBPRL30G and TAPBPR ØG30L were 
able to promote the association of exogenous fluorescent peptide onto cells (Fig. 2a). 
However, when we explored the ability of TAPBPRL30G to mediate fluorescent peptide 
dissociation from HLA-A*68:02, we found that it was incapable of mediating efficient 
peptide dissociation in the presence of unlabelled competitor (Fig. 2c-2e). Strikingly, 
alteration of this single residue had the same effect on the function of TAPBPR as mutating 
the entire loop. The crucial role of L30 in mediating peptide dissociation was further 
supported with our observation that TAPBPRØG30L, in which the leucine residue alone is 
restored into the dysfunctional TAPBPRØloop molecule, transformed it into a functioning 
peptide exchange catalyst on HLA-A*68:02, albeit at reduced capability compared to 
TAPBPRWT (Fig. 2c-2e). While TAPBPRWT efficiently promoted rapid peptide exchange 
at very low concentrations of competitor peptide, both TAPBPRØloop and TAPBPRL30G 
were extremely inefficient at mediating peptide exchange on HLA-A*68:02 molecules, even 
in the presence of high concentrations of competitor peptide (Fig. 2e). These results suggest 
that L30 is a critical residue within the loop of TAPBPR for mediating peptide dissociation 
on HLA-A*68:02.   
 
Soluble TAPBPR lacking L30 cannot facilitate peptide dissociation from HLA-A*68:02 
We have also recently shown that soluble TAPBPR, consisting only of the lumenal domains 
of the wild-type molecule (i.e. lacking its transmembrane region and cytoplasmic tail) can 
also efficiently promote peptide exchange on three MHC I molecules: HLA-A*68:02, HLA-
A2 and H-2Kb [10]. Therefore, we can also use soluble TAPBPR as a second means to assay 
the ability of TAPBPR mutants to mediate efficient peptide exchange on MHC I.  Using this 
approach, the majority of MHC I molecules that TAPBPR will have access to will be folded 
with bound peptides of relativity high affinity expressed on the surface of cells. The lumenal 
domains of the TAPBPR variants with C-terminal His-tags were purified using Ni-affinity 
chromatography from the culture supernatants of transfected 293T cells (Fig. 3a). 
Differential scanning fluorimetry revealed all TAPBPR loop variants had a similar melting 
temperature as TAPBPRWT (Fig. 3b), indicating the alterations made to the loop had not 
significantly affected protein folding and stability. Comparison of the ability of the soluble 
TAPBPR variants to mediate peptide exchange on HLA-A*68:02 molecules on HeLaM cells 
revealed that TAPBPRWT was most efficient, followed by TAPBPRØG30L, which exhibited 
~33% peptide exchange activity relative to TAPBPRWT (in the presence of 10 nM 
ETVSK*QSNV) (Fig. 3c & 3d). However, both TAPBPRL30G and TAPBPRØloop were 
unable to efficiently mediating peptide exchange, displaying only ~3% of the exchange 
activity of TAPBPRWT (in the presence of 10 nM ETVSK*QSNV) (Fig. 3c & 3d). As 
previously shown [10], soluble TAPBPRTN5, a mutant which cannot bind to MHC I, did not 
mediate any peptide exchange (Fig. 3c & 3d).  This hierarchy (WT>ØG30L>L30G>TN5) 
was maintained over a wide range of exogenous TAPBPR concentrations (Fig. 3e). 
Furthermore, the same hierarchical order of peptide exchange efficiency for the variants was 
observed using another HLA-A*68:02 binding peptide, YVVPFVAK*V (Fig. 3c & d).  
 
 
The K22-D35 loop is essential for soluble TAPBPR to bind peptide-loaded MHC I 
When we determined the ability of the soluble TAPBPR variants to bind to HLA-A*68:02, 
TAPBPRWT was the most efficient binder, followed by TAPBPRØG30L (Fig. 4a).  
However, TAPBPRL30G and TAPBPRØloop were unable to make productive interactions 
with surface expressed HLA-A*68:02 (Fig. 4a). As expected, TAPBPRTN5,which has a 
disrupted binding site for MHC I, was unable to bind to cells [6](Fig. 4a). As this inability of 
soluble TAPBPRØloop and TAPBPRL30G to interact with MHC I contradicted our finding 
with their membrane-bound counterparts (Fig. 1e), we determined whether these soluble 
TAPBPR variants could bind to the total cellular MHC I from cell lysates in pull-down 
experiments. All soluble TAPBPR variants (with the exception of TAPBPRTN5) were 
capable of binding significant amounts of MHC I, although less MHC I was detected bound 
to TAPBPRL30G and TAPBPRØloop (Fig. 4b). A major difference between surface MHC I 
on intact cells (Fig. 4a) and total cellular MHC I in detergent (Fig. 4b) is the availability of 
peptide-receptive molecules. Therefore, we speculated that TAPBPR molecules with 
alterations to the loop are still able to bind to peptide-receptive MHC I but are unable to 
physically make MHC I peptide-deficient due to their inability to dissociate peptide. 
Consistent with this, incubation of cells at 26oC, which increases the expression of peptide-
receptive MHC I on the plasma membrane [16-18], resulted in the TAPBPR loop variants, 
but not TAPBPRWT, exhibiting increased binding to cells (Compare Fig. 4c with 4a 
summarised in Fig. 4d). While no significant change was observed in the ability of 
exogenous TAPBPRWT to bind to cells incubated at the lower temperature, a ~7-fold 
increase in binding of TAPBPRL30G and TAPBPRØloop was observed at 26oC compared to 
37oC, and the binding of TAPBPRØG30L increased by ~2.5-fold (Fig. 4d). When given 
access to surface expressed peptide-receptive MHC I upon incubation at 26oC, all soluble 
TAPBPR variants exhibited a corresponding increase in the ability to mediate peptide 
exchange (compare Fig. 3c (37oC) with Fig. 4e (26oC), summarised in Fig. 4f).  These 
findings suggest that TAPBPR variants lacking L30 are indeed able to bind to peptide-
receptive MHC I but are unable to physically make MHC I peptide-deficient due to their 
inability to efficiently facilitate peptide dissociation. Consistent with this, when cells cultured 
at 26oC were incubated with an HLA-A*68:02 binding peptide prior to testing soluble 
TAPBPR binding, the peptide significantly reduced the ability of TAPBPRØloop to bind to 
cells,  while the binding of TAPBPRWT was unaffected (Figure 4- figure supplement 1). 
 
  
 
Mutation of the TAPBPR K22-D35 loop alters the peptide repertoire presented on 
MHC I 
Having shown a role for the K22-D35 loop of TAPBPR in mediating efficient peptide 
dissociation from MHC I, we next determined whether the peptide repertoire presented by 
MHC I molecules was altered in cells upon mutation of the loop. When we compared the 
immunopeptidomes of IFNγ-treated HeLaM-TAPBPRKO cells expressing TAPBPRWT with 
cells expressing TAPBPRØloop, we found significant changes in the peptides presented on 
MHC I (Fig. 5a). 461 peptides were found exclusively in the TAPBPRWT-expressing cells 
and 550 peptides were found exclusively in the cells expressing the Øloop variant (Fig. 5a). 
Label-free quantitation by mass spectrometry revealed that there were also significant 
changes in the abundance of some peptides between TAPBPRWT and TAPBPRØloop, with 
193 peptides exhibiting increased abundance in cells expressing TAPBPRWT (Red circles, 
Fig. 5b) and 222 peptides displaying increased abundance in TAPBPRØloop-expressing cells 
(Blue circles, Fig. 5b). These findings demonstrate that there are significant changes in the 
peptide repertoire presented on MHC I upon mutation of the TAPBPR loop. While there were 
still large differences in the peptide repertoires between TAPBPRWT and TAPBPRØG30L-
expressing cells, based on a presence/absence approach (Fig. 5a), restoration of the leucine 
residue into the loop appeared to somewhat reduce some of the changes observed in peptide 
abundance (Fig. 5b). Assignment of the identified peptides to the MHC I allotype found in 
HeLaM cells revealed a similar HLA distribution between the various loop mutants (Fig. 5c 
& 5d).  
 
Given the ability of surface expressed TAPBPRWT, but not of TAPBPRØloop, to mediate 
peptide dissociation from surface MHC I molecules, as identified in Fig. 2, we performed an 
additional experiment in which the cells were incubated at 37oC in media after harvesting to 
permit the surface expressed TAPBPR (~5% of the total TAPBPR pool in these cells [10]) to 
perform peptide dissociation/exchange on surface expressed MHC I molecules, prior to 
performing immunopeptidomic analysis. While this experiment confirmed the significant 
changes in the peptide repertoire presented on MHC I upon mutation of the TAPBPR loop 
(Fig. 5e & 5f), it also surprisingly revealed a large effect on the peptides assignable to HLA-
A*68:02 between cells expressing TAPBPRWT and TAPBPRØloop (Fig. 5g & 5h). Based 
on a presence/absence approach, only 29% in TAPBPRWT were now assignable to HLA-
A*68:02, compared to 37% for cell expressing TAPBPRØloop-expressing cells (which was 
similar to the results found when the immunopeptidomics was performed immediately after 
cell harvesting (Fig. 5d)). Similarly, abundance analysis revealed >80% of the up-modulated 
peptides in TAPBPRØloop-expressing cells belonged to HLA-A*68:02, compared to only 
~20% of the up-modulated peptides in TAPBPRWT (Fig. 5h). In keeping with this, we 
observed similar alterations in HLA-A*68:02-assignable peptides when the leucine residue 
was restored into the dysfunctional loop (Fig. 5g & 5h), as the ones observed for 
TAPBPRWT. This suggests that TAPBPR with a functional loop is preferentially stripping a 
proportion of peptides from HLA-A*68:02 molecules, but not from the HLA-B or -C 
molecules found in HeLaM cells. To explore this further, we compared the ability of soluble 
TAPBPR to bind to soluble heterotrimeric HLA-A*68:02, -B15:03 or -Cw12:03 molecules 
coupled to beads. This revealed a strong interaction between TAPBPRWT and HLA-A*68:02 
(Figure 5- Source data 1). However, soluble TAPBPRWT failed to bind to heterotrimeric 
HLA-B*15:03 and –Cw12:03 molecules (Figure 5- Source data 1). This preferential 
association of TAPBPR with peptide-loaded HLA-A*68:02 over the other MHC I found in 
HeLaM cells likely explains why we only observe a loss of HLA-A*68:02 peptides in cells 
expressing TAPBPR with a functional loop. Interestingly, this analysis of soluble HLA 
molecules coupled on beads also confirmed the considerable reduction in binding of 
TAPBPR to HLA-A*68:02 upon mutation of the loop (Figure 5- Source data 1). Taken 
together, this data demonstrates that the loop is involved in selecting MHC I peptides within 
cells and highlights the importance of leucine 30 in the peptide selection process, particularly 
for HLA-A*68:02 molecules. 
 
L30 enables TAPBPR to mediate peptide exchange on MHC I molecules that 
accommodate hydrophobic amino acids in their F pocket 
Given the proximity of the TAPBPR loop to the F pocket of MHC I (Fig. 1) and that the L30 
residue of TAPBPR was both necessary and sufficient for efficient peptide exchange on 
HLA-A*68:02 (Fig. 2 & 3), we hypothesised that the TAPBPR loop facilitates peptide 
dissociation by binding into the F pocket, thereby competing with the C-terminus of the 
peptide.  If so, this competitive binding would only be possible for MHC I molecules that 
could accommodate leucine or similar hydrophobic residues in the F pocket. With this in 
mind, we explored the importance of the TAPBPR K22-D35 loop in mediating peptide 
exchange on two other MHC I molecules, HLA-A*02:01 and H-2Kb, which naturally 
accommodate hydrophobic amino acids in their F pocket like HLA-A*68:02. Compared to 
HLA-A*68:02, HLA-A*02:01 accommodates very similar anchor residues in both B and F 
pockets, whereas H-2Kb has a completely different binding motif, with the exception that it 
binds a similar anchor residue in the F pocket (Fig. 6a).  Thus, given that both HLA-A*02:01 
and H-2Kb could potentially accommodate L30 of the TAPBPR loop in their F-pocket, we 
predicted TAPBPR-mediated peptide editing on these two additional MHC I would also be 
dependent on L30.   
As observed above with HLA-A*68:02, we found that TAPBPRWT was the most efficient 
catalyst on both HLA-A*02:01 and H-2Kb, followed by TAPBPRØG30L, while both 
TAPBPRL30G and TAPBPRØloop were least efficient (Fig. 6b & 6c). For example, the 
Øloop, L30G, and ØG30L variants exhibited ~23%, 32% and 54% activity relative to 
TAPBPRWT, respectively when measuring NLVPK*VATV binding onto HLA-A2 
introduced into HeLaM-HLA-ABCKO cells by transduction (Fig. 6c). We observed similar 
trends using another HLA-A2 binding peptide, YLLEK*LWRL, on this cell line, as well as 
when testing peptide binding to HLA-A2 molecules expressed on MCF-7 cells (Figure 6 –
figure supplement 1). For SIINKEK*L binding to H-2Kb expressed on EL4 cells, the Øloop, 
L30G, and ØG30L variants exhibited ~30%, 31%, 85% activity relative to TAPBPRWT, 
respectively (Fig. 6c). Thus, although TAPBPR can still mediate peptide exchange on HLA-
A2 and H-2Kb in the absence of the loop to some extent, the L30 residue in the K22-D35 
loop of human TAPBPR plays a critical role in promoting efficient peptide exchange on 
HLA-A*68:02, HLA-A2 and H-2Kb.  The shared dependency on L30 to enable TAPBPR to 
efficiently mediate peptide exchange on both H-2Kb and HLA-A*68:02 is remarkable, 
considering the low degree of similarity between these two MHC I, both in their amino acid 
sequences and in their binding motifs.  However, the key shared feature between these MHC 
I is that both accommodate hydrophobic residues in their F pocket.  
 
TAPBPR cannot use the loop to efficiently mediate peptide exchange on MHC I 
molecules with F pocket specificities for non-hydrophobic amino acids 
We next tested the role of the TAPBPR loop in catalysing peptide exchange on an MHC I 
molecule that does not accommodate a hydrophobic residue in its F pocket. In order to only 
explore the contributing role of the F-pocket, with minimal other polymorphisms, we chose 
HLA-A*68:01, since it only differs from HLA-A*68:02 by five amino acids [19]. Most of the 
differences between these two HLA are residues dictating the specificity of the F pocket for 
the C-terminal peptide anchor residue. Hence, while both molecules have a similar anchor 
residue in their B pocket, the F pocket of HLA-A*68:02 accommodates an aliphatic residue, 
whereas the F pocket of HLA-A*68:01 accommodates a basic residue (Fig. 6a) [19]. 
Strikingly, in contrast to the three MHC I molecules tested previously (which all bind 
hydrophobic residues in their F pocket), there was a significant impairment in the ability of 
TAPBPRWT to load peptides onto HLA-A*68:01 (Fig. 6b & 6c). Moreover, there was no 
significant difference in the ability of TAPBPR to exchange peptides on HLA-A*68:01 upon 
mutation of the loop, with the different loop variants all exhibiting a similar ability as soluble 
TAPBPRWT to load the fluorescent peptide KTGGPIYK*R onto HLA-A*68:01 expressed 
on HeLaM-HLA-ABCKO cells (Fig. 6b & 6c).  Thus, in contrast to HLA-A*68:02, which is 
extremely receptive to TAPBPR-mediated peptide exchange in a loop-dependent manner, 
HLA-A*68:01 is significantly less responsive to TAPBPR-mediated peptide exchange, which 
only occurs in a loop-independent manner. Therefore, the five amino acid differences 
between these two HLA molecules, three of which are in the F-pocket (Fig. 6d), strongly 
influence the receptivity of these two MHC I molecules to TAPBPR-mediated peptide 
exchange, the efficiency of which appears to be strongly influenced by the ability of the K22-
D35 loop (specifically L30) to interact with the peptide binding groove. These findings 
support the concept that the L30 residue of TAPBPR is capable of binding into the F pocket 
of MHC I in order promote the dissociation of the bound peptide in a competitive manner.   
 
Mutation of residue 116 in the MHC I F pocket alters TAPBPR binding  
Our data thus far is consistent with the L30 residue of the TAPBPR loop binding to the F 
pocket of MHC I molecules which accommodate hydrophobic residues. One residue that 
differs between HLA-A*68:02 and -A*68:01 and was reported to be crucial in determining 
the F pocket specificity of MHC I for peptide residues is the one on position 116 [20]. The 
impact of residue 116 on the F pocket architecture is well highlighted in the crystal structures 
of peptide-bound HLA-A*68:02 and HLA-A*68:01 [19]. Namely, HLA-A*68:02 contains a 
tyrosine on position 116, whereas HLA-A*68:01 has an aspartate (Fig. 7a). As captured in 
the two structures, D116 of HLA-A*68:01 forms strong dipole interactions with both residue 
R114 of the groove and with the arginine on position 9 of the peptide, determining a strong 
preference of the HLA-A*68:01 F pocket for basic anchor residues. In contrast, residue Y116 
of HLA-A*68:02 does not form any interaction with H114, keeping the hydrophobic patches 
of the F pocket in an open conformation, which allows it to accommodate hydrophobic 
peptide residues (Fig. 7a). We believe that this is the reason why the L30 residue of the 
TAPBPR loop has access to the F pocket of HLA-A*68:02, but not to the one of HLA-
A*68:01.  
To explore whether the F pocket specificity of MHC I molecules was indeed crucial for 
allowing TAPBPR-mediated peptide exchange, we altered the F pocket of both HLA-
A*68:02 and -A*68:01, by switching their residues on position 116, producing HLA-
A*68:02Y116D and HLA-A*68:01D116Y. We subsequently tested their ability to bind soluble 
TAPBPR. When transduced into HeLaM-HLA-ABCKO cells, the 116-mutated HLA-A68 
molecules were expressed at equivalent levels as their WT counterparts (Fig. 7b). When we 
tested the ability of soluble TAPBPRWT to bind to cells expressing the HLA-A*68:02 
molecules, strikingly, TAPBPR exhibited extremely low levels of binding to HLA-
A*68:02Y116D compared to HLA-A*68:02WT molecules (Fig. 7c & 7d). Conversely, TAPBPR 
binding to HLA-A*68:01 was significantly enhanced upon mutation of residue 116 from D to 
Y (Fig. 7c & 7d). The influence of altering the F pocket on TAPBPR binding was further 
verified on another MHC I molecule, HLA-A2 (Figure 7 – figure supplement 1). Together, 
these results demonstrate that the binding of TAPBPR to MHC I molecules is directly 
influenced by the architecture of the F pocket.  
 
Mutation of the MHC I F pocket alters TAPBPR-mediated peptide editing  
Next, we tested the ability of TAPBPRWT to mediate peptide exchange on the same panel of 
HLA-A68 molecules. Since HLA-A*68:01 and -A*68:02 have similar residues on position 
114, we hypothesized that swapping their 116 residues might also swap their F pocket 
specificities. Thus, we interrogated the ability of these molecules to bind both the HLA-
A*68:02-specific peptide ETVSK*QSNV, as well as the HLA-A*68:01-specific peptide 
KTGGPIYK*R, in the presence or absence of soluble TAPBPR. While TAPBPRWT 
efficiently mediated the loading of ETVSK*QSNV onto HLA-A*68:02WT molecules, it 
failed to load this peptide onto HLA-A*68:02Y116D molecules (Fig. 7e & 7f). Similarly, 
TAPBPRWT failed to load ETVSK*QSNV onto HLA-A*68:01WT molecules, however 
efficiently loaded this peptide onto HLA-A*68:01D116Y (Fig. 7e & 7f). Moreover, we found 
that while TAPBPRWT could not load KTGGPIYK*R onto HLA-A*68:02WT molecules, it 
could efficiently load this peptide onto HLA-A*68:02Y116D (Fig. 7g & 7h). Likewise, while 
HLA-A*68:01WT could bind KTGGPIYK*R in the presence of TAPBPRWT, no loading of 
this peptide was observed onto HLA-A*68:01D116Y (Fig. 7g & 7h). These results are in 
keeping with the fact that the alterations made to the F pocket of the HLA-A68 molecules, 
and more specifically, to residue 116 alone, have altered peptide specificity. Nonetheless, it is 
interesting that although low levels of TAPBPR binding are observed to both HLA-
A*68:02Y116D and HLA-A*68:01WT, TAPBPR is still capable of mediating peptide exchange 
on these molecule (albeit to a significantly lower extent as compared to their Y116-
containing counterparts) and of loading the correct peptide based on their F pocket anchor.  
 
 
  
Discussion  
Given the discordance regarding the proximity of the TAPBPR loop in relation to the MHC I 
peptide binding groove in the recently captured structures [11,12], and the lack of functional 
evidence to support any role for this loop, it was vital to directly determine whether this loop 
contributed at all to peptide exchange.  Here we reveal that upon mutation of the K22-D35 
loop, TAPBPR retains binding to MHC I but loses its ability to effectively mediate peptide 
dissociation. Thus, our work provides compelling evidence that this loop region is critical for 
TAPBPR to mediate efficient peptide exchange and consequently peptide selection on MHC I 
molecules. We establish that the leucine residue in the loop is both necessary and sufficient 
for TAPBPR to promote peptide dissociation from both human and mouse MHC I molecules, 
which all typically accommodate a hydrophobic amino acid in their F pocket. However, our 
findings also demonstrate that the ability of TAPBPR to exchange peptides is severely 
impaired on MHC I molecules whose F pockets accommodate charged residues. 
Furthermore, TAPBPR-mediated peptide editing in such scenarios occurs in a loop-
independent manner. The differences identified here in the loop-dependency for TAPBPR-
mediated editing amongst the various MHC I molecules are striking, especially when 
comparing HLA-A*68:02 with HLA-A*68:01 which only differ from each other by five 
amino acids, three of which are located around the F pocket. The extreme differences 
between these two HLA-A*68 molecules in regard to their susceptibility to TAPBPR-
mediated peptide exchange has a remarkable resemblance to the findings reported for HLA-
B44 molecules in regard to their dependency on tapasin for optimal peptide selection [1,21]. 
Particularly striking is that residue 116 of HLA I, which severely impacts both the specificity 
and architecture of the F pocket, seems to play a key role in allowing efficient binding of 
TAPBPR to HLA molecules.  
Although mutation of the loop severely impairs the capacity of TAPBPR to dissociate 
peptides from MHC I, it seems that TAPBPR is still able, though to a considerably lower 
extent, to perform this function independently of the loop, across MHC I molecules with 
different binding motifs. This suggests there are additional mechanisms by which TAPBPR is 
capable of mediating peptide exchange on MHC I. These may involve other regions of 
TAPBPR (for example the jack hairpin [12]) and/or could take place according to the recently 
proposed model of negative allosteric release [13]. Chaperone-mediated peptide editing in 
such loop-independent scenarios may occur in a more generic and less efficient manner as 
compared to loop-dependent situations, and may be influenced mainly by the relative stability 
of individual peptide:MHC I complexes. Thus, one can envisage that TAPBPR can associate 
with MHC I molecules containing peptides that are intrinsically prone to dissociation (i.e. 
sub-optimally loaded peptide) in a loop-independent manner.  
 
The functional evidence provided here highlights that the process of peptide editing is 
complex, multifaceted and is likely to involve dynamic movements of the loop region of 
TAPBPR as it probes the contents of the MHC I peptide binding groove. Our findings 
therefore help to explain the ambiguities in the loop conformation identified between the two 
solved crystal structures. Indeed, our data regarding the critical role of different residues in 
the MHC I groove to alter peptide exchange efficiency by TAPBPR may implicate an 
intrinsic difference in the ability of the specific mouse MHC I molecules crystallised with 
TAPBPR to accommodate hydrophobic residues in their F pocket. This may be of particular 
importance in the structure where modifications were made to H-2Dd to help stabilise it in a 
peptide-receptive form [11], which may have occluded the ability of the loop to insert into the 
F pocket.  
 Our findings are supportive of the following molecular mechanism for peptide exchange by 
TAPBPR (Fig. 8). When MHC I enters a state in which the bound peptide partially 
dissociates i.e. “breathes” at the C-terminus from the F pocket, TAPBPR binds to the MHC I 
groove, at this point in a transient manner, inserting its 22-35 loop into the groove. The 
leucine 30 residue of the TAPBPR loop binds into the F pocket of the groove, inhibiting the 
reassociation of the C-terminal anchor residue of the peptide, if hydrophobic, in a competitive 
manner. The resulting high-free energy intermediate allows TAPBPR to force the MHC I into 
a conformation to which it can bind more stably, pulling the α2-1 region of the peptide 
binding groove away from the peptide, as captured in the crystal structures [11,12]. This 
further prevents the rebinding of the peptide to the groove and thus promotes complete 
peptide dissociation. Given its stable interaction with peptide-receptive MHC I molecules, 
TAPBPR prevents these empty MHC I molecules from “crashing” and we speculate that this 
consequently allows binding of incoming peptides with affinities for MHC I above the 
threshold required to outcompete TAPBPR. This final step may share similar features with 
the tug-of-war model that was previously proposed for tapasin [22].    
 
Intriguingly, our data suggests that the loop enables TAPBPR to dissociate peptides with a 
relatively high affinity for MHC I. This ability of TAPBPR to use its loop to lever peptide out 
of the MHC I binding groove is consistent with TAPBPR performing peptide editing after 
tapasin. The identification here of the critical importance of the leucine residue in the 
TAPBPR loop raises interesting questions regarding the different properties of the TAPBPR 
and tapasin loops and how these mediate step-wise editing to ensure optimal peptide loading 
of MHC I.  
We have recently shown that both plasma membrane-targeted TAPBPR and exogenous 
soluble TAPBPR can be used to display immunogenic peptides on cell surface MHC I 
molecules, and, consequently, induce T cell mediated killing of target cells [10]. This 
observation presents previously unappreciated translational opportunities for utilising 
TAPBPR as a future immunotherapeutic. For example, TAPBPR could potentially be used to 
load immunogenic peptides onto tumours to target them from recognition by cytotoxic T 
cells.  Utilising TAPBPR in this manner may promote tumour immunogenicity and, increase 
the clinical efficacy of immune checkpoint inhibitors when used in combination.  Here, we 
have demonstrated the essential role of the TAPBPR loop in the loading of exogenous 
peptides onto cell surface MHC I molecules and highlight the critical importance of 
incorporating this structural motif of TAPBPR in compounds developed with a therapeutic 
intent. Thus, innovative design of the loop may help tailor TAPBPR to specific MHC I 
molecules and/or alter the properties of the immunogenic peptides loaded by TAPBPR. For 
example, insight regarding the loop may allow us to tailor TAPBPR to MHC I molecules on 
which the naturally-occurring loop does not work.  Furthermore, we may also be able to 
improve peptide binding on MHC I molecules on which TAPBPR is already able to work on. 
Consequently, insight into the functional residues of the loop could expand the range of 
patients that may be responsive to TAPBPR-based therapies. 
  
Methods 
Docking of TAPBPR with MHC I  
Dockings of TAPBPR with MHC I were carried out prior to the recent structure 
determination of the TAPBPR:MHC I complex structures. For the docking studies, we used 
our previously determined model for human TAPBPR based on the structure of tapasin [6] 
and human HLA-A2 [23] (PDB ID 3HLA). TAPBPR was manually docked onto MHC I with 
the following restraints: (i) the membrane-proximal domains of each component, α3 of MHC 
I and the IgC domain of TAPBPR were oriented so as to allow these proteins to maintain 
complex formation when membrane-embedded; (ii) the surface shape complementarity of the 
components was maintained; (iii) the side chain of residue T134 of MHC I was kept within 
10 Å of the sidechains of residues E205-Q209 (TN6 patch) and I261 (TN5 patch) on the IgV 
domain of TAPBPR; and (iv) sidechains of E222 and D223 of MHC I were kept within 10 Å 
of the sidechains of residues R335 (TC2) and Q336-S337 (TC3) on the IgC domain of 
TAPBPR. These last two restraints being mutations known to knock out the interaction in 
cells [6] and the relatively loose restraints allowing for some conformational flexibility of the 
components upon complex formation. 
 
Constructs & Cell lines 
HeLaM cells, a variant HeLa cell line that is more responsive to IFN [24](a gift from Paul 
Lehner, University of Cambridge, UK), their modified variants, and HEK-293T (from Paul 
Lehner, University of Cambridge, UK) were maintained in Dulbecco's Modified Eagle's 
medium (DMEM; Sigma-Aldrich, UK), supplemented with 10% fetal calf serum (Gibco, 
Thermo Fisher Scientific), 100 U/ml penicillin and 100 µg/ml streptomycin (Gibco, Thermo 
Fisher Scientific) at 37°C with 5% CO2. All cells were confirmed to be mycoplasma negative 
(MycoAlert, Lonza, UK). Authenticity of HeLaM was verified by tissue typing for HLA 
molecules and by the continuous confirmation that these cell lines had the expected HLA 
class I tissue type monitored by staining with specific HLA antibodies and by mass 
spectrometry.  
TAPBPRWT and TAPBPRTN5 constructs cloned in the lentiviral vector pHRSIN-C56W-
UbEM have previously been described [5,6]. TAPBPRØloop, in which amino acids 
comprising the 22-35 loop were replaced with amino acids glycine, alanine and serine, was 
created from TAPBPRWTpHRSIN-C56W-UbEM using the following procedure: First, 
amino acids 22-28 were replaced using quick-change site-directed mutagenesis using primers 
M22-for and M22-rev (see Table 2 for primer sequences). Subsequently, amino acids 29-35 
were replaced using a two-step PCR. For this, the TAPBPR insert was amplified in two 
separate pieces, starting from each side of the mutation site (primers TAPBPRWT-BamHI-for 
and M29-rev for the N terminus-containing side and primers M29-for and TAPBPRWT-NotI-
rev for the C terminus-containing side). Subsequently, the two pieces bearing complementary 
regions over the mutated site were used in a second PCR reaction to amplify the whole 
TAPBPR mutated insert using primers TAPBPRWT-BamHI-for and TAPBPRWT-NotI-rev. 
TAPBPRL30G and TAPBPRØG30L were generated from TAPBPRWT and TAPBPRØloop 
respectively, using primers L30G-for and L30G-rev or ØG30L-for and ØG30L-rev, by quick 
change site-directed mutagenesis.  
The HLA*68:02WT construct was cloned by consecutive rounds of quick-change site-directed 
mutagenesis, using the HLA-A*68:01WT construct as a template (see Table 3 for primer 
sequences). Since residue 116 was mutated last in this process, the HLA-A*68:02Y116D 
mutant was the final intermediate in this cloning process. The HLA-A*68:01D116Y was cloned 
by quick-change site-directed mutagenesis, using primers A6801-D116Yonly-Fwd and 
A6801-D116Yonly-Rev. The HLA-A2Y116D mutant was cloned by quick-change site-directed 
mutagenesis, using primers A2-Y116D-Fwd and A2-Y116D-Rev. 
 
Reconstitution of the TAPBPR variants into the TAPBPR-knockout HeLaM cell line 
(HeLaM-TAPBPRKO), and HLA into the HeLaM-HLA-ABCKO cells was performed using 
lentiviral transduction and the cells were subsequently cultured as previously described 
[9,25]. Cells were induced with 200 U/ml IFN-γ (Peprotech, UK) for 48–72 h where 
indicated.  
 
 
Expression and purification of TAPBPR protein 
To make secreted forms of the TAPBPR loop variants enumerated above, the lumenal 
domains were cloned into a modified version of the PB-T-PAF vector where the N-terminal 
Protein A fusion was removed and a C-terminal His6 tag introduced and expressed in 293T 
cells using the PiggyBac expression system [26]. 48 h after transfection, cells were 
transferred for at least 5 days into selection media (DMEM supplemented with 10% FBS, 1% 
pen/strep, 3 µg/mL puromycin (Invivogen, San Diego, CA) and 700 µg/mL geneticin 
(Thermo Fisher Scientific, UK). To induce protein expression, cells were harvested and 
transferred into DMEM supplemented with 5% FBS, 1% pen/strep and 2 µg/mL doxycycline 
(Sigma-Aldrich, UK). After 5-7 days, the media was collected and TAPBPR was purified 
using Ni-NTA affinity chromatography. For purity assessment, elution fractions were 
analysed by SDS-PAGE, followed by Coomassie staining  
 
Differential Scanning Fluorimetry (DSF) 
Thermofluor experiments were performed in 96-well low profile clear PCR plates for Viia7 
cyclers (Axygen). Reactions of 20 μl comprised of 5 μg protein, 1x protein Thermal Shift 
Dye (Life Technologies) in PBS pH 7.4. The melting curve was performed using a Viia7 
thermocycler between 20oC and 95oC in 1oC steps with 20 seconds equilibration time per step 
and fluorescence monitored on the ROX channel.  
 
Isolation of HLA peptides  
HLA class I molecules were isolated from HeLaM-TAPBPRKO cells transduced with either 
TAPBPRWT, TAPBPRØloop or TAPBPRØG30L using standard immunoaffinity 
chromatography employing the pan-HLA class I-specific antibody W6/32 (produced in-
house), as described previously [27]. Tissue typing confirmed the HeLaM cells express HLA-
A*68:02, -B*15:03 and –C*12:03. 
 
Analysis of HLA ligands by LC-MS/MS 
Isolated HLA peptides were analysed in five technical replicates. Peptide samples were 
separated by nanoflow high-performance liquid chromatography (RSLCnano, Thermo Fisher 
Scientific, Waltham, MA, USA) using a 50  μm × 25  cm PepMap rapid separation liquid 
chromatography column (Thermo Fisher Scientific) and a gradient ranging from 2.4% to 
32.0% acetonitrile over the course of 90 min. Eluting peptides were analyzed in an online-
coupled LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientific) using a top five CID 
(collision-induced dissociation) fragmentation method. 
 
Database search and HLA annotation 
Spectra were annotated to corresponding peptide sequences by database search of the human 
proteome as comprised in the Swiss-Prot database (20,279 reviewed protein sequences, 
September 27th 2013) by employing the SEQUEST HT search engine [28] (University of 
Washington) integrated into ProteomeDiscoverer 1.4 (Thermo Fisher Scientific). Data 
processing was performed without enzyme specificity, with peptide length limited to 8-12 
amino acids, and methionine oxidation set as dynamic modification. The false discovery rate 
was calculated by the Percolator algorithm [29] and set to 5%. HLA annotation was 
performed using NetMHCpan-4.0 with a percentile rank threshold of 2%.  
 
Label-free quantitation 
We used label-free quantitation (LFQ) as described previously [30] to assess the relative 
HLA ligand abundances between TAPBPRWT, TAPBPRØloop or TAPBPRØG30L 
expressing cells. Briefly, relative quantitation of HLA ligands was performed by calculating 
the area under the curve of the respective precursor extracted ion chromatogram (XIC) using 
ProteomeDiscoverer 1.4 (Thermo Fisher Scientific). For LFQ analysis the total injected 
peptide amount of all samples was normalised prior to LC-MS/MS analysis. Volcano plots 
were computed using an in-house R script (v3.2) and depict pairwise comparisons of the 
ratios of the mean areas for each individual peptide in the five LFQ-MS runs. Significant 
modulation was defined by an adjusted p-value of <0.01 and a fold change of ≥ log2 2-fold 
change, as calculated by two-tailed t-tests implementing Benjamini-Hochberg correction. 
 
MHC class I-binding peptides 
The following fluorescent MHC-class I specific peptides were used (K* represents a lysine 
labelled with 5-carboxytetramethylrhodaime [TAMRA]): ETVSK*QSNV (HLA-A*68:02), 
YVVPFVAK*V (HLA-A*68:02), NLVPK*VATV (HLA-A*02:01), YLLEK*LWRL (HLA-
A*02:01), SIINFEK*L (H-2Kb), and KTGGPIYK*R (HLA-A*68:01).  The following 
unlabeled competitor peptides were used: YVVPFVAKV, which exhibits high affinity of 
HLA-A*68:02 and EGVSEQSNG, a non-binding derived of ETVSEQSNV, obtained by 
replacing its anchor residues (amino acids on positions 2 and 9) with glycine. All peptides 
were purchased from Peptide Synthetics, UK. 
 
Antibodies 
TAPBPR was detected using either PeTe4, a mouse monoclonal antibody (mAb) specific for 
the native conformation of TAPBPR, raised against amino acids 22–406 of human TAPBPR 
[5] that does not cross-react with tapasin [6], or ab57411, a mouse mAb raised against amino 
acids 23–122 of TAPBPR that is reactive to denatured TAPBPR (Abcam, UK). UGT1 was 
detected using the rabbit mAb ab124879 (Abcam). MHC class I heavy chains were detected 
using mAb HC10 [31]. Soluble TAPBPR variants were detected using the mouse anti-
polyhistidine mAb H1029 (Sigma-Aldrich).  A mouse IgG2a isotype control was also used as 
a control (Sigma-Aldrich).  
 
Flow cytometry 
Following trypsinisation, cells were washed in 1% bovine serum albumin (BSA), dissolved in 
1x phosphate-buffered saline (PBS) at 4°C, and then stained for 30 min at 4°C in 1% BSA 
containing with PeTe4 or with an isotype control antibody. After washing the cells to remove 
excess unbound antibody, the primary antibodies bound to the cells were detected by 
incubation at 4°C for 25 min with either goat anti-mouse Alexa-Fluor 647 IgG (Invitrogen 
Molecular Probes, Thermo Fisher Scientific). After subsequent three rounds of washing, the 
fluorescence levels were detected using a BD FACScan analyser with Cytek modifications 
and analysed using FlowJo (FlowJo, LLC, Ashland, OR).  
 
 
Peptide binding Assay 
For peptide binding in the presence of recombinant TAPBPR, the cells were treated with or 
without the indicated concentration of recombinant TAPBPR (unless otherwise indicated, we 
used 100 nM for HLA-A*68:02, 1 µM used for HLA-A*02:01, H-2Kb and HLA-A*68:01). 
After 15 min, the desired TAMRA-labelled peptide was added to the cells and incubated at 
37°C (15 min for HLA-A*68:02, 60 min for HLA-A*02:01 and –A*68:01, or 30 min for H-
2Kb). For experiments performed at 26oC, following cell seeding and IFNγ stimulation at 
37°C for 48 h, cells were transferred at 26°C for another 12 h to allow for the expression of 
sub-optimally loaded MHC I molecules at the cell surface. The TAPBPR and peptide binding 
was then performed as described above, with all incubation steps being performed at 26°C 
instead of 37°C (with the exception of cell trypinisation which was carried out at 37oC). In 
cases where the peptide binding was facilitated by over-expressed TAPBPR, the labelled 
peptide was directly added to the cells, without using recombinant TAPBPR. Following the 
peptide treatment, the cells were washed three times in 1x PBS and harvested. The level of 
bound peptide/cell was determined by flow cytometry, using the YelFL1 channel (Cytek).  
 
Peptide exchange Assay 
IFNγ treated HeLaM-TAPBPRKO cell lines reconstituted with the different TAPBPR variants, 
were treated with 10 nM TAMRA-labelled peptide of interest diluted in opti-MEM for 15 
min at 37°C, as described above. Following the binding step, the peptide-containing media 
was removed, the cells were washed and then treated with media alone or with different 
concentrations of non-labelled peptide for another 15 min at 37°C. The cells were then 
washed and harvested and the level of bound peptide per cell was determined by flow 
cytometry, using the YelFL1 channel (Cytek). 
 
Immunoprecipitation, gel electrophoresis and western blotting 
For TAPBPR immunoprecipitation experiments from cells over-expressing the panel of 
TAPBPR variants, cells were lysed in 1% triton X-100 (VWR, Radnor, PN), Tris-buffered 
saline (TBS) (20 mM Tris-HCl, 150 mM NaCl, 2.5 mM CaCl2) supplemented with 10 mM 
N-ethylmaleimide (NEM), 1 mM phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich), 
and protease inhibitor cocktail (Roche, UK) for 30 min at 4°C. Nuclei and cell debris were 
pelleted by centrifugation at 13,000 × g for 15 min and supernatants were collected. 
Immunoprecipitation was performed with the TAPBPR-specific mAb PeTe4 [5] coupled to 
protein A sepharose (GE Healthcare), at 5 µg antibody per sample, for 2 h at 4°C with 
rotation. Following immunoprecipitation, beads were washed thoroughly in 0.1% detergent-
TBS to remove.  
 
For pulldown experiments using soluble TAPBPR proteins, IFNγ-stimulated HeLa-
TAPBPRKO cells were harvested, lysed and cleared of cell debris as above.  In order to 
remove cellular factors which bind non-specifically to the sepharose beads, the cell lysate 
was pre-cleared by treatment with protein A sepharose alone, for 30 min at 4°C. 
Subsequently, the lysate was aliquoted and incubated with 5 µg of the soluble TAPBPR 
variant for 90 min at 4°C. Immunoprecipitation of soluble TAPBPR was performed using 
PeTe4 as above.  Soluble TAPBPR was detected on western blots with the anti-polyHis 
primary antibody. Gel electrophoresis and Western blot analysis was performed as described 
in Neerincx et al., [9].  
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Figure Legends 
Fig. 1 – TAPBPR loop interactions with MHC I 
(a) Model of TAPBPR (pink) docked onto MHC I (blue) and β2m (cyan) based on interaction 
studies [6]. (b) Top panel, illustration of the proximity of the TAPBPR loop region to the 
peptide-binding groove (viewed from the top of complex shown in panel a). Lower panel, 
schematic diagrams of the amino acid composition of the TAPBPR and tapasin loops 
compared to the length and orientation of a peptide.  (c) Overlay of two recent X-ray 
structures of TAPBPR in complex with MHC I [11,12] (PDB ID 5WER and 5OPI) oriented 
and coloured to illustrate the similarity to our TAPBPR:MHC I complex (panel a). The 
position of the TAPBPR loop is circled (black dashed line). (b) The electron density map 
(2Fo-Fc, green mesh) and the built model (maroon sticks, residues D23-E34) are shown for 
the loop region of TAPBPR (PDB ID 5OPI). Two views of the loop and density are shown 
rotated by 90 degrees. (e) Expression of TAPBPR loop variants in IFNγ treated HeLaM-
TAPBPRKO and their interaction with MHC I and UGT1. Western blotting for calnexin is 
included as a loading control. Representative of three independent experiments. 
 
Fig. 2 –The TAPBPR K22-D35 loop is critical for peptide exchange  
(a) Typical peptide binding when cells gated for expressing high levels of surface TAPBPR 
were incubated with 10 nM YVVPFVAK*V peptide for 15 min at 37oC on IFNγ treated 
HeLaM-TAPBPRKO cells -/+ expression of TAPBPRWT, TAPBPRØloop, TAPBPRL30G or 
TAPBPR ØG30L. (b) Schematic representation of the experimental workflow used to 
compare the efficient peptide exchange by plasma membrane bound TAPBPRWT with the 
plasma membrane bound TAPBPR loop mutants.  (c) Histograms show the level of 
dissociation of YVVPFVAK*V in the absence (blue line) and presence of 100 nM non-
labelled competitor peptide YVVPFVAKV (orange line) or EGVSKQSNG (ETVΔ2/9), a 
peptide in which the anchors which permit HLA-A*68:02 binding are mutated to produce a 
non-binding derivative (black line). Similar patterns of dissociation were found on cells 
incubated at 4oC demonstrating that the peptide exchange occurs directly on the cell surface 
(see Figure 2 – figure supplement 1).  (d & e) Graphs show the percentage of fluorescent 
peptide YVVPFVAK*V remaining in the presence of (d) 100 nM or (e) increasing 
concentrations of the non-labelled competitor peptide YVVPFVAKV as a percentage of the 
bound YVVPFVAK*V observed in the absence of competitor peptide from 4 independent 
experiments.  Error bars show -/+SD.****P≤0.0001, ***P≤ 0.001 using unpaired two-tailed 
t-tests.  
 
Fig. 3 – Soluble TAPBPR loop variants exhibit reduced ability to mediate peptide 
exchange on surface HLA-A*68:02 molecules 
(a) Expression and purity of soluble forms of WT, L30G, ØG30L, and Øloop TAPBPR 
variants after their purification from the culture supernatant using Ni-affinity. (b) Differential 
scanning fluorimetry demonstrates the three TAPBPR loop mutants have equivalent thermal 
denaturation profiles as TAPBPRWT. (c) Histograms of the typical fluorescent peptide 
binding to IFNγ treated HeLaM cells incubated -/+ 100 nM exogenous soluble TAPBPR 
variant for 15 min at 37oC, followed by incubation with 10 nM ETVSK*QSNV or 
YVVPFVAK*V for an additional 15 min. TAPBPRTN5, in which isoleucine at position 261 
is mutated to lysine, to produce a TAPBPR variant which cannot bind to MHC I, is included 
as a control (d) Bar graphs show the reproducibility of results in c. (e) Dose response curves 
of fluorescent peptide binding to IFN-γ treated HeLaM cells incubated with increasing 
concentrations of the soluble TAPBPR variants prior to the addition of 10 nM 
ETVSK*QSNV. Error bars represent MFI -/+ SD from four independent experiments. 
****P≤0.0001 using unpaired two-tailed t-tests.  
 
Fig. 4 – Residues K22-D35 are essential for soluble TAPBPR to bind peptide-loaded 
MHC I 
(a & c) Histograms of soluble TAPBPR loop variant binding to HeLaM-HLA-ABCKO cells 
expressing HLA-A*68:02 incubated with 100 nM TAPBPR at (a) 37oC or (c) 26oC for 30 
min. TAPBPRTN5, a TAPBPR variant which cannot bind to MHC I, is included as a 
negative control (b) TAPBPR pulldowns on IFNγ treated HeLaM-TAPBPRKO cells incubated 
with soluble TAPBPR loop mutants reveal all variants are capable of binding to MHC I, but 
do not bind to UGT1. TAPBPRTN5 is included as a non-MHC binding control. Data is 
representative of three independent experiments. (d) Bar graph comparing soluble TAPBPR 
variant binding to HeLaM-HLA-ABCKO+A*68:02 cells at 37oC with 26oC from three 
independent experiments. Error bars represent -/+SD. (e) Histograms show typical 
fluorescent peptide binding to IFNγ induced HeLaM cells treated -/+ 100 nM soluble 
TAPBPR variants for 15 min at 26oC, followed by incubation with 10 nM ETVSK*QSNV 
for 15 min at 26oC.  (f) Bar graph compares ETVSK*QSNV peptide binding to HeLaM cells 
treated -/+ soluble TAPBPR variants at 37oC with 26oC from three independent experiments. 
Error bars represent -/+ SD. n/s = not significant, *P≤0.05, **P≤0.01, ***P≤ 0.001, 
****P≤0.0001, using unpaired two-tailed t-tests.  
 
Fig. 5 - Mutation of the K22-D35 loop of TAPBPR changes the peptide repertoire 
presented on cells 
Peptides eluted from W6/32-reactive MHC I complex isolated from IFNγ treated HeLaM-
TAPBPRKO expressing either TAPBPRWT, TAPBPRØloop or TAPBPRØG30L were 
analysed using LC-MS/MS. In dataset 1 (a-d) cells were frozen immediately post-
trypsination while in dataset 2 (e-h) cells were allowed to recover in media for 30 min after 
trypsination, before freezing. The sequences of identified peptides are listed in Figure 5 – 
source data 2-7. The comparison of all five technical replicates for the two datasets is shown 
in Figure 5 –figure supplement 1. (a,e) Venn diagrams compare all the identified peptides 
using a presence/absence approach. (b,f) Volcano plots graphically summarise label free 
quantitation, displaying modulated peptides between two cells lines. Colour circles highlight 
the peptide which are differentially expressed between two cell lines after applying an 
adjusted p-value of <0.01. The list of these peptides is available in Figure 5 – source data 8 
& 9.  n= number of significantly modulated peptides, % demonstrates the fraction of 
significantly modulated peptides in a specific cell line compare to all peptides in the 
comparison. (c,d,g,h) Bar graphs summarise the MHC I molecules (HLA-A*68:02, -B*15:03 
or –C*12:03) that the (c,g) identified peptides in a/e, and (d,h) the significantly modulated 
peptides identified in b/f were matched to using the NetMHCpan-4.0. In c and g, peptides not 
successfully assigned are indicated in orange (rest). Analysis of the peptide repertoire from a 
further TAPBPR-loop mutant lacking L30 and from a third biological repeat can be found in 
Figure 5- figure supplement 2 and 3 respectively.  Analysis of the predicted affinity of 
peptides differential modulated upon mutation of the loop (i.e those in b and f) can be found 
in Figure 5- figure supplement 4.  
 
Fig. 6 – F pocket specificity for hydrophobic residues influences the ability of TAPBPR 
to edit peptides in a loop-dependent manner.  
(a) Comparison of the A-F pocket specificities of the HLA-A*68:02, HLA-A*02:01, H-2Kb 
and HLA-A*68:01 peptide binding grooves. (b) Binding of fluorescent peptide to IFNγ-
treated HeLaM-HLA-ABCKO transduced with HLA-A*02:01, mouse EL4 cells (which 
express H-2Kb) or HeLaM-HLA-ABCKO transduced with HLA-A*68:01 -/+ 1 µM soluble 
TAPBPR variant for 15 min at 37oC, followed by incubation with 10 nM NLVPK*VATV 
(HLA-A2 binding peptide) for 60 min, 1 nM SIINFEK*L (H-2Kb binding peptide) for 30 min 
or 100 nM KTGGPIYK*R (HLA-A*68:01) for 60 min at 37oC.  (c) Bar graph summarising 
the peptide exchange by soluble TAPBPR variants as performed in b. Error bars represent 
MFI -/+ SD from four independent experiments. ****P≤0.0001, ***P≤ 0.001, *P≤0.05, using 
unpaired two-tailed t-tests. (d) Structure of MHC I from above the binding groove and the 
different amino acids between HLA-A*68:02 and –A*68:01 highlighted in red. 
 
Fig. 7 - Mutation of the MHC I F pocket alters TAPBPR-mediated peptide editing  
(a) PyMOL images of the binding grooves of HLA-A*68:02 (PDB ID 4HX1) and -A*68:01 
(PDB ID 4HWZ), with residues found at position 116 and 114 highlighted. (b) Histograms 
show the surface expression of HLA-A*68:02WT, -A*68:02Y116D, -A*68:01WT and –
A*68:01D116Y, detected using W6/32, when expressed in HeLa-M-HLA-ABCKO cells. (c, e, g) 
HeLaM-HLA-ABCKO cells expressing the panel of HLA-A*68 molecules were incubated 
with 1 μM of soluble TAPBPR for 15 min at 37oC, followed by either (c) detection of surface 
bound TAPBPR using PeTe4, or incubation with (e) 10 nM ETVSK*QSNV (ETV*) or (g) 
100 nM KTGGPIYK*R (KTG*) peptide for 15 min and 60 min, respectively. In (c) staining 
with an isotype control antibody is included as a control (grey dotted line). While histograms 
in c, e, g are representative images, the bar graphs in d, f, h summarise the MFI of (d) 
TAPBPR binding and (f &h) fluorescent peptide binding in the presence and absence of 
TAPBPR, from three independent experiment +/- SD.  ****P≤0.0001, ***P≤ 0.001, P**≤ 
0.01, *P≤0.05. 
 
Fig. 8 - Proposed model of the peptide exchange mechanism of TAPBPR on MHC class 
I  
Table 1:  Panel of TAPBPR loop mutants  
 
 
 
 
 
 
Table 2 – primers used for cloning and generation of TAPBPR loop mutants 
 
 
 
  
TAPBPR Variant Loop sequence 
WT KDGAHRGALASSED 
Øloop AAGGSGGGGSGGAA 
L30G KDGAHRGAGASSED 
ØG30L AAGGSGGGLGGGAA 
Primer name Primer sequence 5ʹ-3ʹ 
TAPBPRWT- 
BamHI-for 
GCGCGGATCCAGCAGCCTCCATGGGCACACAGGAGGGC 
TAPBPRWT- 
NotI-rev 
GCGCGCGGCCGCTCAGCTGGGCTGGCTTACA 
M22-for 
 
GTCCTAGACTGTTTCCTGGTGGCGGCCGGTGGGAGCGGTGGAG
CTCTCGCCAGCAGTG 
M22-rev CACTGCTGGCGAGAGCTCCACCGCTCCCACCGGCCGCCACCAG
GAAACAGTCTAGGAC 
M29-for GCGGCCGGTGGGAGCGGTGGAGGTGGCAGCGGCGGTG 
M29-rev TCCACCGCTCCCACCGGCCGCCACCAGGAAACAGTCTAGGAC 
L30G-for GTGGAGCTGGCGCCAGCAGT 
L30G-rev ACTGCTGGCGCCAGCTCCAC 
ØG30L-for  GGTGGAGGTCTGGGCGGCGGTGC  
ØG30L-rev GCACCGCCGCCCAGACCTCCACC 
 
Table 3 – primers used for generating HLA mutations  
Primer name Primer Sequence 5'-3' 
A6801_V12M_Fwd CTACACTTCCATGTCCCGGC 
A6801_V12M_Rev GCCGGGACATGGAAGTGTAG 
A6801_M97R_Fwd CACCATCCAGAGGATGTATGGC
A6801_M97R_Rev GCCATACATCCTCTGGATGGTG 
A6801_S105P_Fwd CGTGGGGCCGGACGGGC 
A6801_S105P_Rev GCCCGTCCGGCCCCACG 
A6801_R114H_Fwd GCGGGTACCACCAGGACGCC 
A6801_R114H_Rev GGCGTCCTGGTGGTACCCGC 
A6801_D116Y_Fwd GTACCACCAGTACGCCTACG 
A6801_D116Y_Rev CGTAGGCGTACTGGTGGTAC 
A6801_D116Yonly_Fwd GTACCGGCAGTACGCCTAC 
A6801_D116Yonly_Rev GTAGGCGTACTGCCGGTAC 
A2_Y116D_Fwd GTACCACCAGGACGCCTACG 
A2_Y116D_Rev CGTAGGCGTCCTGGTGGTAC 
 
 
  
Supplementary Figures & Tables 
Figure 2 – figure supplement 1: Peptide Exchange at 4oC 
To ensure peptide exchange was occurring directly on the surface MHC I rather than in 
intracellular vesicles, peptide exchange assays were performed on cells incubated at 4oC to 
inhibit membrane trafficking. HeLa-TAPBPRKO cells reconstituted with the panel of 
TAPBPR loop mutant were cooled to 4oC then incubated with 5 µM ETVSK*QSNV (ETV*) 
for 60 min at 4oC, followed by washing thoroughly in cold PBS to remove unbound peptide. 
Dissociation of the fluorescent peptide was subsequently monitored in the absence (blue line) 
or presence of 1 µM ETVSEQSNV (ETV) (orange line) for 60 min at 4oC.     
 
Figure 4 – figure supplement 1: Pre-incubation with high affinity peptide inhibits 
TAPBPRØloop binding to HLA-A*68:02 molecules at 26oC 
HeLaM-HLA-ABCKO cells reconstituted with HLA-A*68:02 were incubated at 26oC for 12 
hours, then subsequently treated -/+ 1 µM ETVSK*QSNV peptide for 30 min at 26oC, 
followed by washing twice in PBS to remove unbound peptide.  Cells were then incubated 
cells with -/+ 100 nM TAPBPRWT or TAPBPRØloop at 26oC for 15 min, washed in PBS, 
then cooled to 4oC for detection of bound TAPBPR using the mAb PeTe4. (a) Histograms 
show the fluorescent peptide binding to the cells incubated at 26oC used to test soluble 
TAPBPRWT and TAPBPRØloop binding. (b) Histograms show the typical TAPBPRWT and 
TAPBPRØloop binding to cells incubated at 26oC with (red line) and without (black line) 
pre-incubation with the HLA-A*68:02 binding peptide.  (c) Bar chart show the MFI of 
TAPBPR binding from three independent experiments. Error bars represent -/+ SD. The data 
show that pre-incubation of cells with high affinity peptide significantly reduces the ability of 
soluble TAPBPRØloop to bind to HLA-A*68:02 (***P≤ 0.001) but does not significantly 
inhibit the ability of TAPBPRWT to bind to HLA-A*68:02.  
 
Figure 5 – figure supplement 1: Technical reproducibility of LC-MS/MS measurement  
Peptide elution experiments were performed in 5 technical replicates for all cell lines. Column 
analysis reveals the percentage of peptides identified in 1-5 out of 5 technical replicates for (a) 
data set 1 (cells frozen immediately post-trypsinisation) and (b) data set 2 (cells allowed to 
recover for 30 min in media post-trypsinisation before freezing). 
 
Figure 5 – figure supplement 2: Mutation of residue A29-D35 in the loop of TAPBPR 
changes the peptide repertoire presented on cells.  
In addition to the TAPBPRWT, TAPBPRØloop or TAPBPRØG30L analysed in Fig. 5e-h, 
we also performed peptidomic analysis for an additional loop mutation of TAPBPR in which 
residues A29-D35 where mutated from ALASSED to GGSGGAA. Thus, this mutant also 
lacks the leucine 30 residue. Peptides eluted from W6/32-reactive MHC I complex isolated 
from IFNγ treated HeLaM-TAPBPRKO expressing either TAPBPRWT and TAPBPRM29 
were analysed using LC-MS/MS as in dataset 2 in Figure 5 (with recovery in media for 30 
min after trypsination, before freezing). The sequences of identified peptides for 
TAPBPRM29 are listed in Figure 5 – source data 10. (a) Venn diagrams compare all the 
identified peptides using a presence/absence approach. (b) Volcano plots graphically 
summarise label free quantitation, displaying modulated peptides between two cells lines. 
Colour circles highlight the peptide which are differentially expressed between two cell lines 
after applying an adjusted p-value of <0.01. n= number of significantly modulated peptides, 
% demonstrates the fraction of significantly modulated peptides in a specific cell line 
compare to all peptides in the comparison. (c) Bar graphs summarise the MHC I molecules 
(HLA-A*68:02, -B*15:03 or –C*12:03) that the (c) identified peptides in a and (d) the 
significantly modulated peptides identified in b and were matched to using the NetMHCpan-
4.0. In c, peptides not successfully assigned are indicated in orange (rest).  
 
Figure 5 – figure supplement 3: 3rd biological repeat 
Peptides were eluted from W6/32-reactive MHC I complex isolated from a third set of IFNγ 
treated HeLaM-TAPBPRKO expressing either TAPBPRWT, TAPBPRØloop or 
TAPBPRØG30L and analysed using LC-MS/MS. The treatment of these cells is comparable 
to dataset 2 in the main figure 5 (cells were allowed to recover in media for 30 min after 
trypsination, before freezing.   The sequences of identified peptides are listed in Figure 5 – 
source data 11-13. The dataset is based on 3 technical repeats. (a) Venn diagrams compare 
all the identified peptides using a presence/absence approach. (b) Bar graphs summarise the 
MHC I molecules (HLA-A*68:02, -B*15:03 or –C*12:03) that the identified peptides in a 
were matched to using the NetMHCpan-4.0. In b, peptides not successfully assigned are 
indicated in orange (rest). As shown in Fig. 5e & 5g, this additional dataset suggests that 
TAPBPR molecules with a function loop strips peptides from HLA-A*68:02 molecules.  
 
Figure 5- figure supplement 4: peptide affinity predictions using NetMHC 
The affinity of peptides identified as being differentially modulated in the Volcano plots in 
Fig. 5b &5f) were predicted using netMHCpan3.0.  For each comparisons the peptides were 
sorted into the A-/B-/C-alleles using best_NetMHC_Allele.  Peptides with an affinity above 
500 nM were excluded. Box and whiskers plots show the peptide affinities for HLA-
A*68:02, -B*15:03 and C*12:03 for peptides differentially modulated in (a) dataset 1 and (b) 
dataset 2.  As the data-points were not normally distributed, the Mann-Whitney test was used 
to find significant differences between the comparisons. The number of peptides used in the 
analysis is show below each graph.   
 
We feel it is very difficult to draw any definitive conclusions regarding the effect of mutating 
the loop on the affinity of the peptides bound to MHC I from this particular analysis.   Firstly, 
the peptide numbers corresponding to each HLA is low, especially for the HLA-B15 assigned 
peptides from cells expressing the TAPBPR loop mutant. This questions whether the 
significance observed is reliable, particularly for HLA-B15. Secondly, our experimental 
design was set up to explore whether there was a global change in peptide repertoire upon 
mutation of the TAPBPR loop.  Thus, technical limitations regarding the need to assign 
peptides to particular MHC I (by applying thresholds or cut-offs to determine which peptide 
was bound to which MHC I) greatly reduce the ability to detect peptides exhibiting low 
affinity for a particular MHC I. Other studies [17,32,33], exploring the affinity of peptides by 
immunopeptidomics use cells expressing only one MHC I. Therefore, the identified peptides 
do not need to be assigned to MHC I, thus improving the ability to see reliable changes 
(including subtle changes) in anchors and affinity.  A third consideration is that trypsination 
of cells may be cause the loss of low affinity peptide from MHC I molecules.  
 
One interesting observation from this analysis was the affinity of HLA-A*68:02 assigned 
peptides between dataset 1 and dataset 2 for cells expressing TAPBPRWT appeared to 
increase. Thus hinting that surface expressed TAPBPRWT may dissociate low affinity 
peptide from HLA-A*68:02. However, to conclude, from these particular datasets, we are 
unable to address whether there is any change in affinity of MHC I bound peptides upon 
mutation of the TAPBPR loop. Improvement in experimental design will address this in the 
future.     
 
 
 
Figure 6 – figure supplement 1: Peptide loading by soluble TAPBPR onto HLA-A2 
molecules  
(a) Fluorescent peptide binding to IFNγ treated HeLaM-HLA-ABCKO reconstituted with 
HLA-A2 treated -/+ 1 µM soluble TAPBPR variant for 15 min at 37oC, followed by 
incubation with 10 nM YLLEK*LWRL (HLA-A2 binding peptides) for 60 min at 37oC.  
(b) Fluorescent peptide binding to IFNγ treated MCF-7 treated -/+ 1 µM soluble TAPBPR 
variant for 15 min at 37oC, followed by incubation with 10 nM NLVPK*VATV or 
YLLEK*LWRL (HLA-A2 binding peptides) for 60 min at 37oC. Error bars represent MFI -
/+ SD from four independent experiments. ****P≤0.0001, ***P≤ 0.001 using unpaired two-
tailed t-tests.  
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Figure 5 – Source data 1: Binding of TAPBPR to the individual HLA molecules found 
in HeLaM cells 
 
 no TAPBPR TAPBPRWT TAPBPRØloop W6/32 
A*68:02 418.3 (± 31.1) 14461 ±(139) 2576.3 ±(19.6) 23344 
B*15:03 6 (± 10.4) 21.7 ±(2.3) 17.3 ±(1.5) 23670 
C*12:03 146 (±16.8) 249 ±(12) 175 ±(14.8) 23814 
 
Soluble TAPBPRWT or soluble TAPBPRØloop were incubated with the indicated 
LABScreen single antigen HLA class I beads (from One Lambda, Canoga Park, California) 
for 60 min at RT. After washing 3 times in PBS, bound TAPBPR was detected using the 
TAPBPR specific mAb PeTe4 and a goat anti-mouse PE-conjugated secondary antibody. 
Samples were analysed using the Luminex Fluoroanalyser system. The table shows the MFI 
of PeTe4 staining +/- SD for the indicated HLA beads incubated in the absence and presence 
of 1 µM of TAPBPRWT or TAPBPRØloop.  The expression of MHC I (detected using 
W6/32) provided by One Lambda for the specific lot of LABScreen beads used is included as 
a control.  
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